Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12551MR)

This product GTTS-WQ12551MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12551MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15424MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ9000MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ14537MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ4558MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ9819MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ3015MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ15902MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ16007MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZW-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW